Author:
Saldanha Sabita N.,Soni Shivani
Publisher
Springer International Publishing
Reference183 articles.
1. Yang L, et al. Mutations of p53 and KRAS activate NF-kappaB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells. Cancer Lett. 2015;357(2):520–6.
2. Liu J, et al. Tumor suppressor p53 and its mutants in cancer metabolism. Cancer Lett. 2015;356(2 Pt A):197–203.
3. Zhou WQ, et al. Expressions of survivin, P16(INK4a), COX-2, and Ki-67 in cervical cancer progression reveal the potential clinical application. Eur J Gynaecol Oncol. 2015;36(1):62–8.
4. Zhu Z, et al. Mutations in the p16 gene in DMBA-induced pancreatic intraepithelial neoplasia and pancreatic cancer in rats. Hepatobiliary Pancreat Dis Int. 2015;14(2):208–14.
5. Fey MF. p53, myc, APC, hMSH2, ras, etc. in colorectal cancer—a never ending story! Ann Oncol. 1995;6(10):961–2.